Provided by Tiger Trade Technology Pte. Ltd.

Inhibrx Biosciences

83.09
+1.521.86%
Pre-market: 83.390.3000+0.36%08:36 EST
Volume:363.75K
Turnover:30.12M
Market Cap:1.21B
PE:-8.29
High:84.84
Open:80.05
Low:78.69
Close:81.57
52wk High:94.47
52wk Low:10.81
Shares:14.54M
Float Shares:7.81M
Volume Ratio:1.30
T/O Rate:4.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.0252
EPS(LYR):114.01
ROE:-144.07%
ROA:-60.97%
PB:32.81
PE(LYR):0.73

Loading ...

BRIEF-Inhibrx Biosciences, Inc Provides Progress Updates On The Inbrx-106 Program And The Expansion Cohorts Of The Ozekibart (Inbrx-109) Program

Reuters
·
Yesterday

Inhibrx Biosciences Advances INBRX-106 Phase 2/3 Trial for Head and Neck Cancer

Reuters
·
Yesterday

Inhibrx Biosciences Provides Progress Updates on the Inbrx-106 Program and the Expansion Cohorts of the Ozekibart (Inbrx-109) Program

THOMSON REUTERS
·
Yesterday

Inhibrx Biosciences Reports Promising Q3 2025 Results

TIPRANKS
·
Nov 25

Inhibrx options imply 7.3% move in share price post-earnings

TIPRANKS
·
Nov 15

Inhibrx Biosciences Q3 EPS $(2.28) Misses $(1.72) Estimate, Cash And Cash Equivalents Of $153.1M

Benzinga
·
Nov 14

Earnings Flash (INBX) Inhibrx Biosciences Posts Q3 Loss $2.28 a Share

MT Newswires Live
·
Nov 14

Inhibrx Biosciences posts Q3 net loss of $35.3 million

Reuters
·
Nov 14

Inhibrx Q3 Operating Income USD -33.812 Million

THOMSON REUTERS
·
Nov 14

Transcenta’s Partner Inhibrx Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma

TIPRANKS
·
Oct 31

TRANSCENTA-B (06628) Partner Inhibrx Reports Positive Phase II Trial Results for Ozekibart in Chondrosarcoma, Plans BLA Submission by 2026

Stock News
·
Oct 31

Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma

Reuters
·
Oct 31

Inhibrx’s Phase 1 Study of INBRX-109: A Potential Game-Changer in Cancer Treatment

TIPRANKS
·
Oct 28

US Stocks Jump To Records Amid Weak Inflation: Investor Fear Eases, Greed Index Remains In 'Fear' Zone

Benzinga_recent_news
·
Oct 27

Nasdaq Net Change Percentage Gainers & Losers

Dow Jones
·
Oct 25

Top Midday Gainers

MT Newswires Live
·
Oct 25

Stocks Soar To Records After Weak Inflation, Ford Jumps 10%: What's Moving Markets Friday?

Benzinga_recent_news
·
Oct 25

Ford, Inhibrx Biosciences, Comfort Systems, Western Union And Other Big Stocks Moving Higher On Friday

Benzinga
·
Oct 24

Why Are Inhibrx Biosciences Shares Soaring 76% After Hours?

Benzinga
·
Oct 24

BRIEF-Inhibrx Biosciences Reports Positive Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And Provides Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts

Reuters
·
Oct 24